Physician profile
David Patterson
NPI 1457589772
$9,072.24
in general payments reported to CMS, 2019-2025
24 companies · $2,262 in 2025
The $2,262 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,783 · 2022: $1,887 · 2023: $1,460 · 2024: $1,679 · 2025: $2,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,390 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,389.51 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,057.42 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,170.98 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $813.49 | 2021-2025 | Rexulti |
| Lundbeck LLC | $564.71 | 2021-2025 | Rexulti |
| Alkermes, INC. | $558.34 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $529.28 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $528.24 | 2022-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $473.96 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $392.63 | 2021-2025 | Invega Sustenna, Spravato |
| Sunovion Pharmaceuticals INC. | $377.46 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $307.00 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $248.36 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $214.99 | 2021-2024 | Trintellix |
| Indivior INC. | $190.38 | 2022-2024 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $188.30 | 2023-2025 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $99.35 | 2024-2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $76.95 | 2025 | Jornay Pm |
| Biohaven Pharmaceuticals, INC. | $70.77 | 2021 | |
| Neurocrine Biosciences, INC. | $65.52 | 2022-2025 | Ingrezza |
| Biohaven Pharmaceutical Holding Company LTD. | $50.88 | 2022 | |
| Pfizer INC. | $41.49 | 2023-2024 | |
| Lilly USA, LLC | $24.84 | 2025 | Zepbound |
| Eisai INC. | $13.60 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.30 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.